Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbralisib in CLL Intolerant to Prior BTK or PI3K Inhibitors
NCT02742090Phase 2Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Apr 2016
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbralisib in chronic lymphocytic leukemia (CLL), sponsored by TG Therapeutics, Inc. Primary endpoint: Progression-Free Survival up to 61.7 months. Started Apr 2016; status: terminated.
02
Drugs
umbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02742090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742090.